First Trust Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

First Trust Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-29,611	Closed	-$3.02M	–	2530
2023 Q2	$3.02M	Buy	+29,611	New	+$2.8M	﹤0.01%	1499
2021 Q4	–	Sell	-3,946	Closed	-$397K	–	2624
2021 Q3	$397K	Buy	+3,946	New	+$463K	﹤0.01%	2333
2020 Q3	–	Sell	-7,810	Closed	-$1.22M	–	2522
2020 Q2	$1.22M	Sell	7,810 -23,870	-75%	-$3.63M	﹤0.01%	1640
2020 Q1	$4.57M	Sell	31,680 -18,336	-37%	-$3.54M	0.01%	900
2019 Q4	$10.2M	Sell	50,016 -8,220	-14%	-$1.5M	0.02%	843
2019 Q3	$4.68M	Buy	58,236 +6,319	+12%	+$536K	0.01%	1091
2019 Q2	$4.9M	Buy	51,917 +26,441	+104%	+$2.28M	0.01%	1064
2019 Q1	$2.18M	Sell	25,476 -21,722	-46%	-$1.8M	﹤0.01%	1510
2018 Q4	$2.65M	Buy	47,198 +43,976	+1,365%	+$2.68M	0.01%	1312
2018 Q3	$263K	Buy	+3,222	New	+$227K	﹤0.01%	2333

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

First Trust Advisors's RETA Position: Q3 2023 in Review

First Trust Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 29,611 shares — an estimated $3.02M sold.

First Trust Advisors first reported a position in RETA in Q3 2018 and held it in 10 quarters. The position peaked at $10.2M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

First Trust Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
First Trust Advisors sold 29,611 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $3.02M.
First Trust Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 10 quarters.
First Trust Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $10.2M in Q4 2019.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on First Trust Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.